Complete Filing Data
Aprea Therapeutics, Inc. reported Stockholders Equity of $12.44 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Aprea Therapeutics, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$12.6M | -$13.0M | -$14.3M | -$112.7M | -$37.1M | -$53.5M | -$28.1M | -$15.5M | -$15.2M |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -$7.3K | -$16.1K | $12.1K | -$264.5K | -$321.7K | $1.5M | -$2.8M | -$473.9K | $495.2K |
| Other Nonoperating Income Expense | $634.3K | $1.4M | $1.2M | $730.2K | $319.1K | -$667.6K | $1.5M | $961.1K | $662.1K |
| Operating Expenses | $13.5M | $15.8M | $16.1M | $113.4M | $37.4M | $52.8M | $29.5M | $16.5M | $15.9M |
| Interest Income Expense Nonoperating Net | $652.1K | $1.3M | $1.2M | $448.7K | $1.6K | $222.7K | $156.4K | -$182.00 | -$15.00 |
| General And Administrative Expense | $6.5M | $6.5M | $8.4M | $21.0M | $13.6M | $14.9M | $8.6M | $2.3M | $2.5M |
| Comprehensive Income Net Of Tax | -$12.6M | -$13.0M | -$14.3M | -$112.9M | -$37.4M | -$52.0M | -$30.8M | -$16.0M | -$14.7M |
| Research And Development Expense Excluding Acquired In Process Cost | $7.0M | $9.4M | $7.6M | $16.4M | $23.9M | $37.9M | |||
| Research And Development Expense | $23.9M | $37.9M | $21.0M | $14.2M | $13.4M | ||||
| Operating Income Loss | -$13.2M | -$14.3M | -$15.5M | -$113.4M | -$37.4M | ||||
| Revenue Not From Contract With Customer | $285.8K | $1.5M | $583.2K | ||||||
| Deferred Revenue Current | $529.0K | ||||||||
| Research And Development In Process Noncash | $72.5M | ||||||||
| Research And Development In Process | $76.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 | Q3 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$3.0M | -$3.2M | -$3.9M | -$3.8M | -$3.5M | -$2.8M | -$3.2M | -$3.3M | -$4.4M | -$4.0M | -$98.3M | -$7.9M | -$9.5M | -$10.3M | -$9.7M | -$12.3M | -$16.4M | -$9.4M | -$6.2M | -$5.3M | -$3.5M | -$3.1M |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -$1.1K | -$1.7K | $643.00 | $23.6K | -$1.9K | -$15.1K | -$1.0K | -$73.4K | $62.0K | $26.2K | $157.7K | -$65.5K | -$207.6K | $193.0K | -$402.9K | -$169.0K | $1.8M | -$2.4M | -$2.9M | $44.5K | -$2.0M | $65.8K |
| Other Nonoperating Income Expense | $145.0K | $148.9K | $152.9K | $313.2K | $376.9K | $339.6K | $318.3K | $392.6K | $242.6K | $175.5K | $207.1K | $138.2K | -$21.9K | -$253.4K | $520.9K | -$83.8K | -$1.9M | $2.5M | $968.9K | $676.0K | $932.6K | -$207.5K |
| Operating Expenses | $3.1M | $3.5M | $4.2M | $4.5M | $4.4M | $3.5M | $3.8M | $3.9M | $4.6M | $4.2M | $98.5M | $8.1M | $9.4M | $10.0M | $10.2M | $12.2M | $14.5M | $11.9M | $7.2M | $5.9M | $4.4M | $2.9M |
| Interest Income Expense Nonoperating Net | $150.7K | $178.0K | $204.7K | $348.7K | $382.4K | $283.4K | $321.2K | $336.2K | $256.4K | $151.1K | $52.5K | $2.0K | -$33.00 | -$588.00 | -$1.1K | -$9.2K | $2.7K | $224.4K | -$6.1K | -$4.1K | -$3.3K | $4.00 |
| General And Administrative Expense | $1.5M | $1.6M | $1.8M | $1.6M | $1.9M | $1.9M | $1.7M | $1.7M | $3.4M | $3.1M | $15.6M | $4.0M | $3.4M | $3.3M | $3.4M | $3.5M | $3.8M | $2.8M | $2.3M | $1.6M | $729.3K | $623.7K |
| Comprehensive Income Net Of Tax | -$3.0M | -$3.2M | -$3.9M | -$3.8M | -$3.5M | -$2.8M | -$3.2M | -$3.3M | -$4.3M | -$4.0M | -$98.1M | -$8.0M | -$9.7M | -$10.1M | -$10.1M | -$12.5M | -$14.6M | -$11.8M | -$9.2M | -$5.2M | -$5.5M | -$3.1M |
| Research And Development Expense Excluding Acquired In Process Cost | $1.6M | $1.9M | $2.5M | $2.8M | $2.6M | $1.6M | $2.1M | $2.2M | $1.3M | $1.1M | $6.8M | $4.1M | $6.0M | $6.7M | ||||||||
| Research And Development Expense | $4.1M | $6.0M | $6.7M | $6.8M | $8.8M | $10.7M | $9.1M | $4.9M | $4.3M | $3.7M | $2.3M | |||||||||||
| Operating Income Loss | -$3.1M | -$3.4M | -$4.1M | -$4.1M | -$3.8M | -$3.1M | -$3.5M | -$3.7M | -$4.6M | -$4.2M | -$98.5M | |||||||||||
| Revenue Not From Contract With Customer | $1.8K | $118.1K | $162.5K | $354.6K | $561.6K | $380.6K | $319.5K | $249.7K | ||||||||||||||
| Deferred Revenue Current | $50.7K | $148.4K | ||||||||||||||||||||
| Research And Development In Process Noncash | ||||||||||||||||||||||
| Research And Development In Process | $76.0M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $12.4M | $19.3M | $17.0M | $25.6M | $49.5M | $77.4M | $124.2M | -$51.4M | -$35.8M | -$21.5M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $14.6M | $22.9M | $21.6M | $28.8M | $53.1M | $89.0M | $130.1M | $65.7M | $24.4M | $13.7M |
| Cash And Cash Equivalents At Carrying Value | $14.6M | $22.8M | $21.6M | $28.8M | $53.1M | $89.0M | $130.1M | $65.7M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$8.3M | $1.2M | -$7.1M | -$24.3M | -$35.9M | -$41.7M | $65.8M | $41.1M | $9.3M | |
| Retained Earnings Accumulated Deficit | -$333.6M | -$321.0M | -$308.1M | -$293.8M | -$181.1M | -$144.0M | -$90.5M | -$62.5M | ||
| Property Plant And Equipment Net | $59.8K | $81.5K | $88.4K | $2.3K | $23.9K | $38.5K | $41.6K | $24.5K | ||
| Prepaid Expense And Other Assets Current | $961.9K | $726.3K | $914.3K | $1.4M | $3.5M | $3.4M | $3.0M | $322.1K | ||
| Liabilities Current | $2.8M | $3.4M | $4.4M | $3.2M | $7.3M | $15.3M | $9.1M | $4.9M | ||
| Liabilities And Stockholders Equity | $15.9M | $24.0M | $22.7M | $30.2M | $56.8M | $92.8M | $133.6M | $66.0M | ||
| Common Stock Value | $8.2K | $5.5K | $3.7K | $2.7K | $1.1K | $21.2K | $21.0K | $127.1K | ||
| Assets Current | $15.6M | $23.6M | $22.5M | $30.2M | $56.6M | $92.4M | $133.0M | $66.0M | ||
| Assets | $15.9M | $24.0M | $22.7M | $30.2M | $56.8M | $92.8M | $133.6M | $66.0M | ||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$10.6M | -$10.6M | -$10.6M | -$10.6M | -$10.4M | -$10.0M | -$11.5M | -$8.8M | ||
| Accrued Liabilities And Employee Related Liabilities Current | $2.1M | $2.0M | $2.2M | $2.4M | $5.4M | $10.6M | $6.6M | $3.1M | ||
| Accounts Payable Current | $713.7K | $1.4M | $1.7M | $842.8K | $1.8M | $4.5M | $2.2M | $1.7M | ||
| Other Assets Noncurrent | $271.2K | $281.7K | $29.4K | $29.4K | $107.00 | $111.00 | ||||
| Liabilities | $7.3M | $15.4M | $9.4M | $4.9M | ||||||
| Operating Lease Right Of Use Asset | $185.8K | $320.6K | $521.4K | |||||||
| Operating Lease Liability Current | $190.5K | $256.3K | $242.3K | |||||||
| Restricted Cash | $41.2K | $40.2K | $40.7K | |||||||
| Restricted Cash Noncurrent | $41.2K | $40.2K | $40.7K | |||||||
| Operating Lease Right Of Use Asset Amortization Expense | $182.0K | $258.8K | $200.8K | $159.1K | ||||||
| Operating Lease Liability Noncurrent | $78.8K | $302.6K | ||||||||
| Operating Lease Right Of Use Asset Amortization | $200.8K | $159.1K | ||||||||
| Capital Lease Obligations Incurred | $123.8K | $124.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 | Q3 2018 | Q2 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $10.9M | $13.4M | $15.5M | $21.9M | $25.6M | $28.9M | $20.3M | $23.4M | $26.5M | $26.6M | -$35.8M | $43.6M | $53.4M | $61.0M | $69.1M | $89.0M | $100.1M | $113.4M | -$70.8M | -$61.9M | -$56.8M | -$47.5M | -$44.5M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $13.8M | $16.6M | $19.3M | $26.3M | $28.7M | $32.4M | $25.4M | $27.7M | $31.0M | $33.1M | $39.1M | $47.7M | $61.4M | $69.8M | $77.6M | $101.1M | $112.9M | $122.5M | $52.3M | $61.0M | $65.7M | $12.4M | ||
| Cash And Cash Equivalents At Carrying Value | $13.7M | $16.5M | $19.3M | $26.2M | $28.7M | $32.4M | $25.4M | $27.7M | $31.0M | $33.1M | $39.1M | $47.7M | $61.4M | $69.8M | $77.6M | $101.1M | $112.9M | $122.5M | $52.3M | |||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$3.6M | $10.8M | $2.2M | -$5.5M | -$11.5M | -$7.5M | $1.2M | |||||||||||||||||
| Retained Earnings Accumulated Deficit | -$331.2M | -$328.2M | -$325.0M | -$318.1M | -$314.4M | -$310.9M | -$304.6M | -$301.4M | -$298.2M | -$291.4M | -$287.3M | -$189.1M | -$173.4M | -$163.9M | -$153.7M | -$128.6M | -$116.3M | -$99.9M | -$77.5M | |||||
| Property Plant And Equipment Net | $65.2K | $70.7K | $76.1K | $87.0K | $92.4K | $90.2K | $86.2K | $1.7K | $1.9K | $12.2K | $20.3K | $20.6K | $27.3K | $31.0K | $33.6K | $40.7K | $43.9K | $45.9K | $31.0K | |||||
| Prepaid Expense And Other Assets Current | $225.9K | $395.0K | $558.7K | $234.2K | $865.1K | $698.9K | $286.3K | $953.7K | $1.0M | $361.2K | $1.4M | $2.4M | $750.9K | $1.5M | $2.5M | $1.3M | $1.5M | $2.1M | $339.8K | |||||
| Liabilities Current | $2.7M | $3.2M | $3.4M | $3.6M | $3.1M | $3.0M | $4.2M | $4.0M | $4.2M | $4.0M | $7.7M | $6.7M | $9.0M | $10.6M | $11.2M | $13.7M | $14.5M | $11.5M | $9.6M | |||||
| Liabilities And Stockholders Equity | $14.3M | $17.3M | $20.2M | $26.9M | $30.0M | $33.2M | $25.8M | $28.7M | $32.0M | $33.6M | $40.7M | $50.3M | $62.5M | $71.5M | $80.4M | $102.8M | $114.8M | $125.1M | $57.3M | |||||
| Common Stock Value | $6.0K | $5.8K | $5.5K | $5.4K | $5.4K | $5.4K | $3.7K | $3.7K | $3.7K | $52.2K | $23.4K | $22.0K | $21.4K | $21.2K | $21.2K | $21.2K | $21.2K | $21.1K | $1.2K | |||||
| Assets Current | $13.9M | $16.9M | $19.8M | $26.5M | $29.6M | $33.1M | $25.6M | $28.6M | $32.0M | $33.5M | $40.5M | $50.0M | $62.2M | $71.3M | $80.1M | $102.4M | $114.3M | $124.6M | $56.7M | |||||
| Assets | $14.3M | $17.3M | $20.2M | $26.9M | $30.0M | $33.2M | $25.8M | $28.7M | $32.0M | $33.6M | $40.7M | $50.3M | $62.5M | $71.5M | $80.4M | $102.8M | $114.8M | $125.1M | $57.3M | |||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$10.6M | -$10.6M | -$10.6M | -$10.6M | -$10.6M | -$10.6M | -$10.6M | -$10.6M | -$10.6M | -$10.2M | -$10.3M | -$10.4M | -$10.5M | -$10.2M | -$10.4M | -$12.4M | -$12.2M | -$14.0M | -$13.7M | |||||
| Accrued Liabilities And Employee Related Liabilities Current | $2.0M | $2.0M | $2.1M | $2.5M | $2.1M | $1.5M | $3.3M | $2.8M | $3.4M | $2.8M | $3.5M | $4.5M | $6.3M | $8.0M | $7.5M | $9.1M | $8.8M | $8.3M | $5.8M | |||||
| Accounts Payable Current | $641.3K | $1.2M | $1.3M | $1.2M | $964.3K | $1.3M | $862.6K | $1.1M | $826.0K | $1.1M | $4.0M | $2.0M | $2.5M | $2.4M | $3.5M | $4.3M | $5.4M | $3.0M | $3.5M | |||||
| Other Assets Noncurrent | $271.2K | $271.2K | $271.2K | $281.7K | $271.2K | $29.4K | $29.4K | $29.4K | $29.4K | $29.4K | $29.4K | $29.4K | $29.4K | $29.4K | $102.00 | |||||||||
| Liabilities | $4.0M | $4.2M | $3.2M | $4.0M | $7.7M | $6.7M | $9.1M | $10.6M | $11.2M | $13.8M | $14.7M | $11.8M | $9.9M | |||||||||||
| Operating Lease Right Of Use Asset | $106.5K | $171.0K | $242.2K | $248.8K | $191.1K | $248.2K | $360.6K | $408.8K | $445.5K | $560.3K | ||||||||||||||
| Operating Lease Liability Current | $110.6K | $189.1K | $219.5K | $224.0K | $199.2K | $225.5K | $244.3K | $241.5K | $238.8K | $226.9K | ||||||||||||||
| Restricted Cash | $40.9K | $40.7K | $40.4K | $41.5K | $41.3K | $41.0K | $40.4K | $40.2K | ||||||||||||||||
| Restricted Cash Noncurrent | $40.9K | $40.7K | $40.4K | $41.5K | $41.3K | $41.0K | $40.4K | $40.2K | ||||||||||||||||
| Operating Lease Right Of Use Asset Amortization Expense | $60.8K | $72.4K | ||||||||||||||||||||||
| Operating Lease Liability Noncurrent | $28.1K | $29.8K | $33.8K | $132.8K | $185.9K | $227.3K | $358.4K | |||||||||||||||||
| Operating Lease Right Of Use Asset Amortization | $72.4K | $64.0K | $25.8K | |||||||||||||||||||||
| Capital Lease Obligations Incurred | $123.8K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$12.9M | -$13.6M | -$12.2M | -$25.0M | -$37.7M | -$41.8M | -$26.7M | -$15.3M | -$14.0M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $217.9K | $96.7K | -$452.0K | -$2.2M | $109.3K | $472.4K | $2.6M | $19.5K | -$4.0K |
| Increase Decrease In Accrued Liabilities | -$64.5K | -$115.5K | -$189.7K | -$2.9M | -$5.2M | $3.9M | $3.5M | $706.9K | $1.1M |
| Increase Decrease In Accounts Payable | -$646.7K | -$314.2K | $827.5K | -$858.5K | -$2.7M | $2.3M | $437.5K | $214.4K | $327.1K |
| Employee Benefits And Share Based Compensation Noncash | $478.1K | $489.4K | $444.5K | $17.0M | $7.8M | $5.0M | $1.3M | $329.2K | $395.4K |
| Depreciation Depletion And Amortization | $21.7K | $22.3K | $7.1K | $4.4K | $12.8K | $28.8K | $11.1K | $8.3K | $7.9K |
| Net Cash Provided By Used In Financing Activities | $4.6M | $14.8M | $5.1M | $683.0K | $1.7M | $150.9K | $92.6M | $56.4M | $23.3M |
| Increase Decrease In Operating Lease Liabilities | -$186.7K | -$268.7K | -$209.8K | -$154.3K | |||||
| Payments To Acquire Property Plant And Equipment | $15.5K | $93.1K | $25.7K | $30.9K | $3.7K | ||||
| Net Cash Provided By Used In Investing Activities | -$15.5K | -$93.1K | -$25.7K | -$30.9K | -$3.7K | ||||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $4.7K | -$7.2K | -$8.4K | $38.8K | -$2.5K | $606.2K | |||
| Proceeds From Issuance Of Common Stock | $5.0M | $16.1M | $5.8M | $683.0K | $1.5M | ||||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -$2.5K | $606.2K | -$1.4M | $161.6K | $1.4M | ||||
| Proceeds From Stock Options Exercised | $208.4K | $150.9K | $71.0K | $2.1K | |||||
| Payments Of Stock Issuance Costs | $407.5K | $1.3M | $648.9K | ||||||
| Increase Decrease In Deferred Revenue | -$529.0K | $529.0K | |||||||
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $2.6M | ||||||||
| Proceeds From Issuance Of Convertible Preferred Stock | $5.6M | ||||||||
| Proceeds From Issuance Initial Public Offering | $86.9M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q2 2022 | Q1 2022 | Q1 2021 | Q1 2020 | Q1 2019 |
|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$3.6M | -$3.9M | -$3.0M | -$5.5M | -$11.5M | -$7.5M | -$4.2M | |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$181.0K | -$213.6K | -$344.1K | -$1.1M | -$931.6K | -$864.9K | -$57.9K | |
| Increase Decrease In Accrued Liabilities | $16.5K | -$644.4K | $1.0M | -$840.4K | -$3.0M | $1.7M | -$145.6K | |
| Increase Decrease In Accounts Payable | -$71.9K | -$350.3K | -$16.7K | $215.0K | -$1.0M | $829.8K | $202.3K | |
| Employee Benefits And Share Based Compensation Noncash | $118.6K | $85.8K | $16.2K | $2.1M | $1.8M | $905.5K | $97.9K | |
| Depreciation Depletion And Amortization | $5.4K | $6.2K | $410.00 | $2.9K | $3.6K | $3.8K | $2.1K | |
| Net Cash Provided By Used In Financing Activities | $55.8K | $14.7M | $5.1M | $29.5K | $5.4M | |||
| Increase Decrease In Operating Lease Liabilities | -$60.1K | -$75.9K | -$217.7K | -$26.8K | ||||
| Payments To Acquire Property Plant And Equipment | $8.0K | $12.2K | ||||||
| Net Cash Provided By Used In Investing Activities | -$8.0K | -$12.2K | ||||||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $1.4K | -$2.4K | $48.2K | $71.1K | ||||
| Proceeds From Issuance Of Common Stock | $59.2K | $16.0M | $5.8M | |||||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $71.1K | $120.5K | -$51.2K | -$1.2M | ||||
| Proceeds From Stock Options Exercised | $29.5K | $23.1K | ||||||
| Payments Of Stock Issuance Costs | $3.4K | $1.3M | $648.9K | |||||
| Increase Decrease In Deferred Revenue | -$380.6K | |||||||
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $2.6M | |||||||
| Proceeds From Issuance Of Convertible Preferred Stock | $5.6M | |||||||
| Proceeds From Issuance Initial Public Offering |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$1.93 | -$2.35 | -$3.95 | -$67.99 | -$34.88 | -$50.61 | -$4.67 | -$13.45 | -$13.17 |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.11 | |
| Weighted Average Number Of Shares Outstanding Basic | 6.5M | 5.5M | 3.6M | 1.7M | 1.1M | 1.1M | 6.0M | ||
| Weighted Average Number Of Diluted Shares Outstanding | 6.5M | 5.5M | 3.6M | 1.7M | 1.1M | 1.1M | 6.0M | ||
| Earnings Per Share Basic | $-1.93 | $-2.35 | $-3.95 | $-67.99 | $-34.88 | $-50.61 | $-4.67 | ||
| Common Stock Shares Outstanding | 8.2M | 5.5M | 3.7M | 2.7M | 1.1M | 21.2M | 21.0M | 1.2M | |
| Common Stock Shares Issued | 8.2M | 5.5M | 3.7M | 2.7M | 1.1M | 21.2M | 21.0M | 1.2M | |
| Common Stock Shares Authorized | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | ||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 21.1M | 6.0M | 1.2M | 1.2M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 | Q3 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.47 | -$0.53 | -$0.66 | -$0.64 | -$0.58 | -$0.67 | -$0.86 | -$0.87 | -$1.34 | -$2.32 | -$86.72 | -$7.25 | -$0.45 | -$0.48 | -$0.46 | -$0.58 | -$0.78 | -$0.45 | -$5.29 | -$4.45 | -$2.97 | -$2.72 |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Weighted Average Number Of Shares Outstanding Basic | 6.4M | 6.1M | 6.0M | 5.9M | 5.9M | 4.2M | 3.7M | 3.7M | 3.3M | 1.7M | 1.1M | 1.1M | 21.2M | 21.2M | 21.2M | 21.2M | ||||||
| Weighted Average Number Of Diluted Shares Outstanding | 6.4M | 6.1M | 6.0M | 5.9M | 5.9M | 4.2M | 3.7M | 3.7M | 3.3M | 1.7M | 1.1M | 1.1M | 21.2M | 21.2M | 21.2M | 21.2M | ||||||
| Earnings Per Share Basic | $-0.47 | $-0.53 | $-0.66 | $-0.64 | $-0.58 | $-0.67 | $-0.86 | $-0.87 | $-1.34 | $-2.32 | $-86.72 | $-7.25 | $-0.45 | $-0.48 | $-0.46 | $-0.58 | ||||||
| Common Stock Shares Outstanding | 6.0M | 5.8M | 5.5M | 5.4M | 5.4M | 5.4M | 3.7M | 3.7M | 3.7M | 52.2M | 23.4M | 22.0M | 21.4M | 21.2M | 21.2M | 21.2M | 21.2M | 21.1M | 1.2M | |||
| Common Stock Shares Issued | 6.0M | 5.8M | 5.5M | 5.4M | 5.4M | 5.4M | 3.7M | 3.7M | 3.7M | 52.2M | 23.4M | 22.0M | 21.4M | 21.2M | 21.2M | 21.2M | 21.2M | 21.1M | 1.2M | |||
| Common Stock Shares Authorized | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | ||||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 21.2M | 21.2M | 21.2M | 21.1M | 21.1M | 1.2M | 1.2M | 1.2M | 1.2M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $478.1K | $489.4K | $444.5K | $17.0M | $7.8M | $5.0M | $1.3M | $329.2K | $395.4K |
| Foreign Currency Transaction Gain Loss Before Tax | -$95.3K | $71.8K | -$38.9K | $281.5K | $317.4K | -$890.3K | $1.3M | $961.3K | $662.1K |
| Additional Paid In Capital | $356.7M | $351.0M | $335.6M | $330.1M | $241.0M | $231.4M | $226.3M | $19.7M | |
| Stock Issued During Period Value New Issues | $2.7M | $14.7M | $4.9M | $683.0K | $1.5M | $100.00 | |||
| Stock Issued During Period Value Stock Options Exercised | $208.4K | $150.9K | $71.0K | $2.1K | |||||
| Stock Issued During Period Value Conversion Of Convertible Securities | $583.7K | $67.5M | $118.2M | ||||||
| Stock Issued1 | $70.1M | ||||||||
| Adjustments To Additional Paid In Capital Stock Issued Issuance Costs | |||||||||
| Stock Issued During Period Value Acquisitions | $1.3M | ||||||||
| Noncash Cumulative Effect Of Change In Accounting Principle | |||||||||
| Stock Issued During Period Value Issued For Services | $39.1K | $17.4K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 | Q3 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $113.8K | $136.7K | $118.6K | $149.1K | $128.5K | $85.8K | $76.0K | $269.3K | $16.2K | $38.2K | $14.8M | $2.1M | $2.0M | $1.9M | $1.8M | $1.4M | $1.3M | $905.5K | $246.2K | $187.0K | $97.9K | $79.8K |
| Foreign Currency Transaction Gain Loss Before Tax | -$5.7K | -$29.1K | -$51.8K | -$35.5K | -$5.5K | $56.2K | -$2.9K | $56.4K | -$13.8K | $24.4K | $154.6K | $136.2K | -$21.9K | -$252.8K | $522.0K | -$74.6K | -$1.9M | $2.2M | $975.0K | $680.1K | $935.9K | -$207.5K |
| Additional Paid In Capital | $352.7M | $352.3M | $351.1M | $350.7M | $350.5M | $350.4M | $335.6M | $335.5M | $335.2M | $328.2M | $261.8M | $243.1M | $237.2M | $235.1M | $233.2M | $230.0M | $228.6M | $227.2M | $20.3M | |||
| Stock Issued During Period Value New Issues | $14.7M | $4.9M | $584.4K | $100.00 | ||||||||||||||||||
| Stock Issued During Period Value Stock Options Exercised | $87.0K | $121.4K | $29.5K | $23.1K | ||||||||||||||||||
| Stock Issued During Period Value Conversion Of Convertible Securities | $583.7K | $65.8M | ||||||||||||||||||||
| Stock Issued1 | ||||||||||||||||||||||
| Adjustments To Additional Paid In Capital Stock Issued Issuance Costs | $1.2K | $21.1K | ||||||||||||||||||||
| Stock Issued During Period Value Acquisitions | $1.3M | |||||||||||||||||||||
| Noncash Cumulative Effect Of Change In Accounting Principle | $329.4K | |||||||||||||||||||||
| Stock Issued During Period Value Issued For Services |
Most recent annual filing with the SEC: March 16, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.